Dresden

• VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended
  2022-500079-30-00 5 2022-11-03 IgA Nephropathy
• Study to evaluate the efficacy and safety of fedratinib in combination with CC-486 in patients suffering from myelofibrosis in acute phase. Ended
  2024-519227-22-00 9 2022-11-03 Myeloproliferative neoplasm in accelerated phase (MPN-AP)
• A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IG … Ended
  2024-512244-36-00 10 2022-10-25 Thyroid eye disease (TED)
• Zibotentan and Dapagliflozin combination, Evaluated in Liver cirrhosis (ZEAL study) Ended
  2023-505405-17-00 4 2022-10-07 Liver cirrhosis with features of portal hypertension.
• MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma Ended
  2023-503615-14-00 4 2022-09-29 Relapsed or Refractory Classical Hodgkin Lymphoma
• Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission Ended
  2024-512856-40-00 5 2022-09-21 Giant Cell Arteritis
• Clinical study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and … Ended
  2024-514788-24-00 5 2022-09-20 Chronic stable plaque psoriasis
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended
  2024-513992-42-00 10 2022-09-13 venous thromboembolism (VTE) in patients with gastrointestinal/genitou
• Early Reperfusion Therapy for Recovery of Vision in Acute Central Retinal Artery Occlusion Ended
  2023-507388-21-00 5 2022-09-08 Acute non-arteritic central retinal artery occlusion (CRAO)
• A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Ended
  2024-510729-24-00 6 2022-09-01 Chronic Migrane, Migrane, Medication Overuse Headache
• Personalized dosing of immunosuppression after kidney transplantation by measuring the immune system functionality Ended
  2022-500024-30-00 4 2022-08-23 Post Kidney transplantation
• A multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the rate of weekly lipoprotein apheresis ses … Ended
  2023-508324-35-00 5 2022-08-19 Apheresis
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatm … Ended
  2024-513658-31-00 4 2022-08-08 Idiopathic Sudden Sensorineural Hearing Loss
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and … Ended
  2023-508734-34-00 10 2022-06-30 Pulmonary Arterial Hypertension (PAH)
• Treprostinil Palmitil Inhalation Powder for Pulmonary Arterial Hypertension Ended
  2023-505541-99-00 4 2022-06-28 Pulmonary Arterial Hypertension
• Phase 2 Study to Assess Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction (≤45%) After Myocardial I … Ended
  2023-507569-24-00 4 2022-06-20 Myocardial Infarction, Acute Heart Failure, Left Sided
• A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alon … Ended
  2023-506981-30-00 4 2022-05-25 Chronic kidney disease in type 2 diabetes mellitus
• A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients. Ended
  2023-509139-16-00 5 2022-05-13 Therapeutic confirmatory (phase III)
• A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid Ended
  2023-508645-40-00 10 2022-05-10 Bullous Pemphigoid (BP)
• Safety and preliminary efficacy trial of BNT142 in patients with CLDN6-positive advanced ovarian, lung, or testicular cancer Ended
  2024-512639-58-00 7 2022-05-07 Solid Tumors
• A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low … Ended
  2024-514758-65-00 7 2022-05-04 metastatic castration-resistant prostate cancer (mCRPC)
• An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult … Ended
  2024-515832-59-00 5 2022-05-03 Bullous Pemphigoid

Showing 841–864 of 943 trials